For example, a newer generation of PMO conjugated with cell-penetrating peptides (PPMO) has proven positive clinical results from a phase II trial with DMD patients, in terms of dystrophin restoration with respect to the naked analogue sequence [22]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.